Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics

SYDNEY, July 12, 2011 -

Australian biotech company Clinical Genomics Pty Ltd today
announced agreement with Quest Diagnostics, the world’s leading
provider of diagnostic testing, information and services, to extend
a strategic alliance between the two companies related to Clinical
Genomics’ proprietary biomarkers for colorectal cancer and
precancerous colorectal cancer tumors. Under the agreement, Quest
Diagnostics will make milestone payments to Clinical Genomics for
the development and validation of new molecular blood tests for the
early detection of colorectal cancer. Clinical Genomics has been
awarded payments after successfully achieving key research and
development goals. Additional terms were not disclosed.

“There is a growing need for noninvasive blood tests that can
aid the detection of colorectal cancer or precancerous polyps in
the earliest, most treatable stages,” said Dr. Lawrence LaPointe,
CEO of Clinical Genomics. “Quest Diagnostics is leading the
industry in developing blood and fecal immunochemical tests for
aiding colorectal cancer detection. By extending our alliance with
Quest Diagnostics, we will continue to transition Clinical
Genomics’ research of colorectal cancer gene targets into clinical
testing services for the large, underserved market of the United
States and other countries.”

Quest Diagnostics offers a broad menu of colorectal cancer
tests, including the ColoVantage(TM) blood test for aiding the
detection of colon cancer for patients in the United States, and
the InSure(R) fecal immunochemical test (FIT), manufactured by the
company’s Sydney-based Enterix Inc. business and available in
Australia and the United States.

Colorectal cancer is the second most common cause of cancer
death of both men and women in the United States, according to the
American Cancer Society. Although five-year survival for detected
early-stage colorectal cancer is about 90 percent, some patients
resist colonoscopy and other methods and never get screened.
According to results of a recent poll co-sponsored by Quest
Diagnostics, three in four people would be more likely to be
screened for colon cancer if a blood test were available.

About Clinical Genomics

Clinical Genomics is a Sydney-based biotechnology company formed
in 2006 to exploit the patented and patent-pending gene expression
biomarkers for colorectal cancer discovered by its founders and
Flinders University in 2001. Clinical Genomics continues to work
closely with Flinders University and the Commonwealth Scientific
and Industrial Research Organisation (CSIRO) in Australia to
advance the development of products that will improve the detection
and management of colorectal neoplasia.  Additional
information is available at: href="www.clinicalgenomics.com/">www.clinicalgenomics.com

Further Information:
Dr. Lindsay Collinson
Clinical Genomics Pty Ltd
Ph: +61-2-9888-9065
E: Lindsay.collinson@clinicalgenomics.com

.